

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Young Caroline</u>  (Last) (First) (Middle) 1600 WEST END AVENUE SUITE 1300  (Street) NASHVILLE TN 37203  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [ CPIX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2025	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/01/2025		P	V	8 <sup>(1)</sup>	A	\$3.56	32,661	D	
Common Stock	07/02/2025		P	V	8 <sup>(1)</sup>	A	\$3.52	32,669	D	
Common Stock	07/03/2025		P	V	8 <sup>(1)</sup>	A	\$3.531	32,677	D	
Common Stock	07/07/2025		P	V	8 <sup>(1)</sup>	A	\$3.23	32,685	D	
Common Stock	07/08/2025		P	V	8 <sup>(1)</sup>	A	\$3.06	32,693	D	
Common Stock	07/09/2025		P	V	8 <sup>(1)</sup>	A	\$3.05	32,701	D	
Common Stock	07/10/2025		P	V	8 <sup>(1)</sup>	A	\$3.2	32,709	D	
Common Stock	07/11/2025		P	V	8 <sup>(1)</sup>	A	\$3.21	32,717	D	
Common Stock	07/14/2025		P	V	8 <sup>(1)</sup>	A	\$3.46	32,725	D	
Common Stock	07/15/2025		P	V	8 <sup>(1)</sup>	A	\$3.45	32,733	D	
Common Stock	07/16/2025		P	V	8 <sup>(1)</sup>	A	\$3.79	32,741	D	
Common Stock	07/17/2025		P	V	8 <sup>(1)</sup>	A	\$3.82	32,749	D	
Common Stock	07/18/2025		P	V	8 <sup>(1)</sup>	A	\$3.59	32,757	D	
Common Stock	07/21/2025		P	V	8 <sup>(1)</sup>	A	\$3.45	32,765	D	
Common Stock	07/22/2025		P	V	8 <sup>(1)</sup>	A	\$3.47	32,773	D	
Common Stock	07/23/2025		P	V	8 <sup>(1)</sup>	A	\$3.54	32,781	D	
Common Stock	07/24/2025		P	V	8 <sup>(1)</sup>	A	\$3.55	32,789	D	
Common Stock	07/25/2025		P	V	8 <sup>(1)</sup>	A	\$3.37	32,797	D	
Common Stock	07/28/2025		P	V	6 <sup>(1)</sup>	A	\$3.47	32,803	D	
Common Stock	07/29/2025		P	V	6 <sup>(1)</sup>	A	\$3.33	32,809	D	
Common Stock	07/30/2025		P	V	6 <sup>(1)</sup>	A	\$3.55	32,815	D	
Common Stock	07/31/2025		P	V	6 <sup>(1)</sup>	A	\$3.5	32,821	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

--

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Deemed Execution Date, if any (Month/Day/Year)	5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Transaction Code (Instr. 8)	Number of Securities						
<b>Explanation of Responses:</b> 1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2024.											
<b>Remarks:</b> <a href="#">Caroline Young by /s/ John Hamm as attorney-in-fact</a> Date: 08/11/2025											
<b>Reminder:</b> Report on a separate line for each class of securities beneficially owned directly or indirectly.											

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.